AT7519

AT7519

• CAS Number: 844442-38-2
• UNSPSC Description: AT7519 (AT7519M) as a potent inhibitor of CDKs, with IC50s of 210, 47, 100, 13, 170, and <10 nM for CDK1, CDK2, CDK4 to CDK6, and CDK9, respectively.
• Target Antigen: Apoptosis; CDK
• Type: Reference compound
• Related Pathways: Apoptosis;Cell Cycle/DNA Damage
• Applications: Cancer-Kinase/protease
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/at7519.html
• Purity: 99.76
• Solubility: DMSO : ≥ 50 mg/mL
• Smiles: O=C(NC1=CNN=C1C(NC2CCNCC2)=O)C3=C(Cl)C=CC=C3Cl
• Molecular Weight: 382.24448
• References & Citations: [1]Santo L, et al. AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition. Oncogene. 2010 Apr 22;29(16):2325-36.|[2]Squires MS, et al. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines.|[3]Squires MS, et al. AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples. Mol Cancer Ther. 2010 Apr;9(4):920-8.Adv Sci (Weinh). 2024 Jan 6:e2305260.|bioRxiv. 2024 September 07.|Dev Biol. 2024 Jan 28:508:93-106.|Exp Eye Res. 2023 Jan 22;227:109391.|FASEB J. 2024 Apr 30;38(8):e23628.|Glycobiology. 2022 Jun 16;cwac038.|Harvard Medical School LINCS LIBRARY|Oncogene. 2023 Oct 16.|RNA Biol. 2021 Sep 30;1-8.|Sci Rep. 2021 Mar 8;11(1):5374.|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.|Cell Chem Biol. 2018 Feb 15;25(2):135-142.e5.|Harvard Medical School LINCS LIBRARY
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
• Clinical Information: Phase 2